Uppsala, Sweden, 2015-09-03 08:15 CEST (GLOBE NEWSWIRE) --
FIRST QUARTER May 1 – July 31, 2015
- Consolidated Net sales amounted to TSEK 219 (994)[1]
- Operating income was TSEK -37,819 (-30 351)
- Net income after tax amounted to TSEK -39,819 (-32 989)
- Earnings per share was SEK -0.41 (-0.38)
- Comprehensive income was TSEK -39,804 (-32 989)
- Oasmia filed a registration statement on listing at NASDAQ USA.
- Oasmia regained the global rights to Paccal Vet and Doxophos Vet and established a sales company in the USA.
EVENTS AFTER THE CLOSING DAY
- Oasmia published positive results for Paclical in a head-to-head comparative study with Abraxane.
CEO COMMENTS:
”We took a number of important steps for the future development of the company during the first quarter. We reclaimed the global distribution and sales rights for Paccal Vet and Doxophos Vet. This was facilitated by an official restructuring within Zoetis, Oasmia’s previous distributor. Oasmia will not have any direct costs related to the reclaim. Due to this, we have established a subsidiary in the USA which will be responsible for sales and marketing of our product on the American market as of October 1. We are currently working intensively to build our own sales organization and expand the portfolio by acquiring further products. We are looking forward to a close collaboration with American veterinaries to provide them with a new treatment option which can extend the lives of their patients.
To further strengthen our presence in the USA, we have registered an application of listing on NASDAQ USA.
After the closing date of the quarter, we were pleased to present results from a study which showed that Paclical and Abraxane had an almost identical pharmacokinetic profile for women with metastatic breast cancer. This is a strong indication that both pharmaceuticals have a similar effect, although Paclical does not contain any human albumin. In the light of this, we are looking forward to a new exciting phase in Oasmia’s development. Abraxane, marketed by Celgene, is the only similar product currently on the market and sales is estimated to exceed one billion USD in 2015”, comments Mikael Asp, CEO of Oasmia.
[1]The numbers in parentheses show the results from the corresponding period of the previous year
Anders Lundin, CFO
Tel: +46 70 209 63 00
E-mail: anders.lundin@oasmia.com
